Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K on October 30, 2018, in connection with its de-SPAC transaction with Avista Healthcare Public Acquisition Corp, a blank-check company sponsored by Avista Capital Partners. The SPAC completed its initial public offering in 2016 and targeted the healthcare sector, ultimately combining with Organogenesis, a Canton, Massachusetts-based regenerative medicine and advanced wound care company. The 2018 business combination brought Organogenesis to Nasdaq under the ORGO ticker, giving the company access to public capital markets to support its portfolio of bioactive and acellular wound care products. Sign up for full data, filings history, and deal analytics on SpacDesk.